Pharmaceutical compositions and treatment methods

Details Pharmaceutical compositions and treatment methods Pharmaceutical compositions and treatment methods

2008-07-08

2008-07-08

Pryor, Alton (Department: 1616)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Cyclopentanohydrophenanthrene ring system doai

Reexamination Certificate

active

07396827

ABSTRACT:
The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of 16α-bromo-3β-hydroxy-5α-androstan-17-one and compositions useful in such dosing regimens. The invention further provides compositions and methods to inhibit pathogen (viral) replication, ameliorate symptoms associated with immune dysregulation and to modulate immune responses in a subject using certain steroids and steroid analogs. The invention also provides methods to make and use these immunomodulatory compositions and formulations.

REFERENCES:
patent: 4039669 (1977-08-01), Beyler et al.
patent: 4055641 (1977-10-01), Benson et al.
patent: 4096254 (1978-06-01), Benson et al.
patent: 4507289 (1985-03-01), Coleman
patent: 4602008 (1986-07-01), Krsek
patent: 4628052 (1986-12-01), Peat
patent: 4654298 (1987-03-01), Babb et al.
patent: 4886655 (1989-12-01), Griffin
patent: 4956355 (1990-09-01), Prendergast
patent: 5001119 (1991-03-01), Schwartz et al.
patent: 5077284 (1991-12-01), Loria
patent: 5116828 (1992-05-01), Miura et al.
patent: 5137882 (1992-08-01), Holt
patent: 5157031 (1992-10-01), Schwartz et al.
patent: 5162365 (1992-11-01), Chinn et al.
patent: 5162371 (1992-11-01), Rothlein et al.
patent: 5206008 (1993-04-01), Loria
patent: 5292730 (1994-03-01), Lardy
patent: 5296481 (1994-03-01), Partridge et al.
patent: 5364847 (1994-11-01), Labrie et al.
patent: 5387583 (1995-02-01), Loria
patent: 5407684 (1995-04-01), Loria
patent: 5424463 (1995-06-01), Lardy
patent: 5461042 (1995-10-01), Loria
patent: 5478566 (1995-12-01), Loria
patent: 5489581 (1996-02-01), Daynes et al.
patent: 5494899 (1996-02-01), Kincade et al.
patent: 5506221 (1996-04-01), Anderson et al.
patent: 5506223 (1996-04-01), Lardy
patent: 5518725 (1996-05-01), Daynes et al.
patent: 5519051 (1996-05-01), Koizumi et al.
patent: 5527788 (1996-06-01), Svec et al.
patent: 5527789 (1996-06-01), Nyce
patent: 5532230 (1996-07-01), Daynes et al.
patent: 5562910 (1996-10-01), Daynes et al.
patent: 5583126 (1996-12-01), Daynes et al.
patent: 5585371 (1996-12-01), Lardy
patent: 5591733 (1997-01-01), Bolger et al.
patent: 5635496 (1997-06-01), Daynes et al.
patent: 5641768 (1997-06-01), Loria
patent: 5660835 (1997-08-01), Nyce
patent: 5681964 (1997-10-01), Ashton et al.
patent: 5686436 (1997-11-01), Van Dyke
patent: 5686438 (1997-11-01), Daynes et al.
patent: 5700793 (1997-12-01), Schwartz et al.
patent: 5709878 (1998-01-01), Rosenbaum
patent: 5714481 (1998-02-01), Schwartz et al.
patent: 5744462 (1998-04-01), Schwartz et al.
patent: 5753237 (1998-05-01), Daynes et al.
patent: 5763433 (1998-06-01), Morfin
patent: 5776923 (1998-07-01), Labrie
patent: 5811418 (1998-09-01), Daynes et al.
patent: 5817650 (1998-10-01), McGuire et al.
patent: 5824313 (1998-10-01), Daynes et al.
patent: 5824668 (1998-10-01), Rubenfield et al.
patent: 5827841 (1998-10-01), Daynes et al.
patent: 5837269 (1998-11-01), Daynes et al.
patent: 5840272 (1998-11-01), Subramanian
patent: 5859000 (1999-01-01), Dowell et al.
patent: 5883074 (1999-03-01), Boggs et al.
patent: 5912240 (1999-06-01), Loria
patent: 5919465 (1999-07-01), Daynes et al.
patent: 5922701 (1999-07-01), Araneo
patent: 5977095 (1999-11-01), Araneo et al.
patent: 5981547 (1999-11-01), Wu et al.
patent: 5994402 (1999-11-01), Rotstein et al.
patent: 6013642 (2000-01-01), Foulkes et al.
patent: 6046185 (2000-04-01), Burgoyne et al.
patent: 6087351 (2000-07-01), Nyce
patent: 6090800 (2000-07-01), Unger et al.
patent: 6117446 (2000-09-01), Place
patent: 6143736 (2000-11-01), Upasani et al.
patent: 6187767 (2001-02-01), Araneo et al.
patent: 6194400 (2001-02-01), Nefkins et al.
patent: 6277838 (2001-08-01), Upasani et al.
patent: 6350738 (2002-02-01), Savage et al.
patent: 6372732 (2002-04-01), Lardy et al.
patent: 6667299 (2003-12-01), Ahlem et al.
patent: 2002/0187973 (2002-12-01), Labrie
patent: 2004/0024231 (2004-02-01), Ring et al.
patent: 2006/0063749 (2006-03-01), Ahlem et al.
patent: 2006/0073099 (2006-04-01), Frincke et al.
patent: 2006/0079492 (2006-04-01), Ahlem et al.
patent: 2006/0088473 (2006-04-01), Dowding et al.
patent: 38 12 595 (1998-10-01), None
patent: 0 133 995 (1985-03-01), None
patent: 0 289 327 (1988-11-01), None
patent: 0429187 (1994-01-01), None
patent: 0 934 745 (1999-08-01), None
patent: 0 494 224 (2000-05-01), None
patent: 930590 (1995-02-01), None
patent: 930811 (1995-05-01), None
patent: 950377 (1996-11-01), None
patent: WO 97/38695 (1997-10-01), None
patent: WO 98/47516 (1998-10-01), None
patent: WO 99/52532 (1999-10-01), None
patent: WO 00/32201 (2000-06-01), None
patent: WO 0032176 (2000-06-01), None
patent: WO 0032177 (2000-06-01), None
patent: WO 00/56757 (2000-09-01), None
U.S. Appl. No. 10/602,330, (claims only), Ahlem et al.
U.S. Appl. No. 10/606,524, (claims only), Ahlem et al.
U.S. Appl. No. 10/607,035, (claims only), Ahelm et al.
U.S. Appl. No. 10/607,415, (claims only), Ahlem et al.
U.S. Appl. No. 10/741,929, (claims only), Ahlem et al.
Amin, et al, Superinduction of Cyclooxygenase-2 Activity in Human Osteoarthritis-affected Cartilage, J. Clin. Invest., 1997, pp. 1231-1237, vol. 99, No. 6.
Amrani, et al., Mechanisms underlying TNF-a effects on agonist-mediated calcium homeostasis in human airway smooth muscle cells, 1997, pp. L1020-L1028.
Anderson, et al., Selective Inhibition of Cyclooxygenase (COX)-2 Reverses Inflammation and Expression of COX-2 and Interleukin 5 in Rat Adjuvant Arthritis, J. Clin. Invest., 1996, pp. 2672-2679, vol. 97, No. 11.
Day, et al., The Prognostic and Pathophysiologic Role of Pro- and Antiinflammatory Cytokines in Severe Malaria, J Infect. Diseases, 1999, pp. 1288-1297.
Douni, et al., A Critical Role of the p75 Tumor Necrosis Factor Receptor (p75NF-R) in Organ Inflammation Independent of TNF, Lymphotoxin a, or the p55TNF-R, J. Exp. Med., 1998, pp. 1343-1352, vol. 188, No. 7.
Elias, et al., Airway remodeling in asthma, J. Clin. Investigation, 1999, pp. 1001-1006, vol. 104, No. 8.
Hallsworth, et al., Cultured Human Airway Smooth Muscle Cells Stimulated by Interleukin-1B Enhance Eosinophil Survival, Am. J. Respir. Cell Mol. Biol., 1998, pp. 910-919, vol. 19.
Huaux, et al., Lung Fibrosis Induced by Silica Particles in NMRI Mice is Associated with an Upregulation of the p40 Subunit of Interleukin-12 and Th-2 Manifestations, Am. J. Respir. Cell Mol. Biol., 1999, pp. 561-572, vol. 20.
Hirst, et al., Airway Smooth Muscle as a Target of Glucocorticoid Action in the Treatment of Asthma, 1998, Am. J. Respir. Crit. Care Med., pp. S201-S206, vol. 158.
Hotta, et al., TNF-a upregulates Gia and Gqa protein expression and function in human airway smooth muscle cells, 1999, Am J Physiol Lung Cell Mol Physiol, pp. L405-L441, vol. 276, Issue 3.
Houglum, et al., TNF-a inhibits liver collagen-a1 (I) gene expression through a tissue-specific regulatory region, 1998, Am J Physiol Gastrointest Liver Physiol, pp. G840-G847, vol. 274, Issue 5.
Kemeny, et al., CD8 T Cell Subsets and Chronic Obstructive Pulmonary Disease, 1999, Am. J. Respir. Crit. Care Med., pp. S33-S37, vol. 160.
Kimata, et al., Slective Inhiition of Spontaneous IgE and IgG4 Production by Interleukin-8 in Atopic Patients, 1995, Blood, pp. 3191-3198, vol. 85, No. 11.
Kwiatkowsi, et al., Anti-TNF therapy inhibits fever in cerebral malaria, 1993, Quarterly J. of Med., pp. 91-98, vol. 86.
Marshall, et al., The acute respiratory distress syndrome: fibrosis in the fast lane, 1998, Thorax, pp. 815-817, vol. 53.
McInnes, et al., Production of Nitric Oxide in the Synovial Membrane of Rheumatoid and Osteoarthritis Patients, 1996, J. Exp. Med., pp. 1519-1524, vol. 184.
Moreland, et al., Treatment of Rheumatoid Arthritis with a Recombinant Human Tumor Necrosis Factor Receptor (p75)-FC Fusion Protein, 1997, The New England J. of Med., pp. 141-147, vol. 337, No. 3.
Reading,

Affiliated with

Also associated with

Rating

Pharmaceutical compositions and treatment methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pharmaceutical compositions and treatment methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions and treatment methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2752685